Asian Pacific Society of Cardiology Consensus Statements on the Management of Worsening Heart Failure
Heart failure (HF) patients in the Asia-Pacific region face multiple challenges with disease management, such as the suboptimal use of optimised medical therapy immediately after discharge and during the maintenance phase of treatment. Because recent evidence underscores the profound benefit of rapid uptitration of optimised medical therapy in HF patients upon discharge, there is a need to improve the quality of care provided to patients with worsening HF in the region. Hence, the Asian Pacific Society of Cardiology (APSC) developed these consensus recommendations, with general cardiologists and internal medicine specialists practising cardiology as the intended readers, to guide them in the appropriate evaluation and management of worsening HF. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral’. The resulting 26 statements provide guidance for clinical practitioners in the Asia-Pacific region on the optimal management of worsening HF.
Authors
- Sanjay Mittal (ORCID: https://orcid.org/0000-0002-3066-1067)
- Shiro Ishihara (ORCID: https://orcid.org/0000-0001-9377-4301)
- Byung‐Su Yoo (ORCID: https://orcid.org/0000-0002-3395-4279)
- Andrew Paul Sindone (ORCID: https://orcid.org/0000-0003-0075-805X)
- Rochelle Regina Cruz (ORCID: https://orcid.org/0000-0003-3783-8192)
- Azmee Mohd Ghazi (ORCID: https://orcid.org/0000-0003-1623-404X)
- Jack Wei Chieh Tan (ORCID: https://orcid.org/0000-0003-2181-4313)
- Yi-Heng Li
- Arintaya Phrommintikul (ORCID: https://orcid.org/0000-0003-3986-1951)
- Hawani Sasmaya Prameswari (ORCID: https://orcid.org/0000-0001-6409-3646)
- Alexandre Mebazaa (ORCID: https://orcid.org/0000-0001-8715-7753)
- Michael Wong Ka Lam
- Yee M. Wong (ORCID: https://orcid.org/0000-0003-3358-7752)
- Yuhui Zhang (ORCID: https://orcid.org/0000-0002-5158-0645)
- Weiqin Lin (ORCID: https://orcid.org/0000-0001-8319-504X)
- Quang Ngoc Nguyen (ORCID: https://orcid.org/0000-0001-7614-9889)
- Feras Bader (ORCID: https://orcid.org/0009-0003-4384-2670)
- David Sim (ORCID: https://orcid.org/0000-0002-5136-9460)
- Louis Teo
Institutions
- Medanta The Medicity (IN)
- The University of Sydney (AU)
- Inserm (FR)
- National University of Singapore (SG)
- Hanoi Medical University (VN)
- Yonsei University (KR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Université Paris Cité (FR)
- Concord Repatriation General Hospital (AU)
- Grantham Hospital (CN)
- Tan Tock Seng Hospital (SG)
- Dr. Hasan Sadikin General Hospital (ID)
- National University Heart Centre Singapore (SG)
- Medanta The Medicity (IN)
- Hôpital Lariboisière (FR)
- National Heart Institute (MY)
- National Heart Centre Singapore (SG)
- Philippine Heart Center (PH)
- Social Insurance Saitama Chuo Hospital (JP)
- National Cheng Kung University Hospital (TW)
- Fu Wai Hospital (CN)
- Chiang Mai University (TH)
- Saitama Medical University (JP)
Publication Details
- Journal
- Journal of Asian Pacific Society of Cardiology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.15420/japsc.2025.31
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- AstraZeneca